SCHEMBL7185571

SCHEMBL7185571

CCOC(=O)C(=S)N(C)Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.56
NPC1 O15118 3/20 0.56
CA12 O43570 2/20 0.51
CA9 Q16790 2/20 0.51
KMT2A Q03164 5/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
MGLL Q99685 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
ALDH1A1 P00352 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
HTT P42858 1/20 0.49
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
HSD17B10 Q99714 1/20 0.49
RIPK1 Q13546 1/20 0.49
TSPO P30536 1/20 0.48
MAPK1 P28482 1/20 0.47
MEN1 O00255 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7790927 0.84 RAB9A (0.59) RAB9ANPC1CA12CA9KMT2A
SCHEMBL9506390 0.80 RAB9A (0.62) RAB9ANPC1CA12CA9KMT2A
SCHEMBL11190772 0.76 RAB9A (0.72) RAB9ANPC1CA12CA9KMT2A
SCHEMBL7415243 0.76 RAB9A (0.53) RAB9ANPC1CA12CA9KMT2A
SCHEMBL19357125 0.76 KMT2A (0.58) RAB9ANPC1CA12CA9KMT2A
SCHEMBL3163935 0.74 NPC1 (0.75) RAB9ANPC1CA12CA9KMT2A
SCHEMBL10861409 0.74 KMT2A (0.55) RAB9ANPC1CA12CA9KMT2A
SCHEMBL7329972 0.73 ALDH1A1 (0.51) KMT2ASMN1; SMN2ALDH1A1L3MBTL1MAPK1
SCHEMBL180384 0.73 NPC1 (0.73) RAB9ANPC1CA12CA9KMT2A
SCHEMBL17423415 0.73 ALDH1A1 (0.50) RAB9ANPC1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6583177-B2 Amidinophenol derivatives as leukotriene B4 (LTB4)antagonists, phospholipase A2 inhibitors, and trypsin inhibitors. ONO PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US disclosed
US-20020128315-A1 Leukotriene B4 antagonist compounds and method for treatment NAKAI HISAO (JP) 2002-09-12 US disclosed
US-6262114-B1 NOVEL AMIDINOPHENOL DERIVATIVES; INHIBITORS OF PHOSPHOLIPASE A2 AND/OR TRYPSIN ONO PHARMACEUTICAL CO., LTD. (JP) 2001-07-17 US disclosed
EP-0703216-B1 Amidinophenol derivatives as protease inhibitors ONO PHARMACEUTICAL CO (JP) 1999-04-07 EP disclosed
EP-0703216-A1 Amidinophenol derivatives as protease inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1996-03-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128315-A1 Leukotriene B4 antagonist compounds and method for treatment LTB4R2, LTB4R, LTA4H RAB9A 3978/4885NPC1 2698/4885CA12 3321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.